Anthem Biosciences Sets IPO Price Band as Expansion Plans Unfold
Anthem Biosciences announces an IPO price range of Rs 540-570, aiming to raise Rs 3,395 crore solely through an offer-for-sale. Revenue grew 30%, reaching Rs 1,844 crore. Anthem focuses on innovation-driven CRDMO activities and plans substantial capacity expansion. Listed peers include Sai Life Sciences and Divi's Laboratories.
- Country:
- India
Anthem Biosciences has announced a price band of Rs 540-570 per share for its forthcoming Rs 3,395-crore initial public offering (IPO), planned to open for public subscription from July 14-16. This move values the company at over Rs 31,800 crore at the upper end of the spectrum.
The IPO, scheduled entirely as an offer-for-sale, implies that the proceeds will benefit existing shareholders without adding any direct funds to the company's coffers. Anthem specializes in contract research and manufacturing operations, producing complex, fermentation-based pharmaceutical ingredients.
The company is aggressively expanding its manufacturing capacities in India, with new facilities expected to be operational by F26. Anthem's financial performance saw a 30% revenue growth in FY25, while its shares are set to debut on the BSE and NSE by July 21.
(With inputs from agencies.)
ALSO READ
Mapex AI Revolutionizes Geospatial Intelligence with Global Expansion
Eternal's Quick Commerce Push Faces Profit Challenges Amid Expansion
Eton Solutions Secures $58 Million Series C for Global Expansion
Renault Appoints Stephane Deblaise to Spearhead Indian Expansion
Transforming Energy: India’s Massive Transmission Network Expansion
Google News